{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:39:23Z","timestamp":1777937963627,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Alemtuzumab-induced diffuse alveolar haemorrhage (DAH) is a rare but serious complication in people with relapsing-remitting multiple sclerosis (RRMS). Evidence supporting retreatment despite adverse events remains limited. We report a 29-year-old female who developed DAH during the first alemtuzumab cycle and was subsequently retreated 1\u2009year later following interdisciplinary advice from respiratory. There was no recurrence of DAH. This case report provides evidence towards retreatment feasibility with regular monitoring and low thresholds for laboratory and radiological investigations.<\/jats:p>","DOI":"10.1177\/13524585251365791","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T07:18:42Z","timestamp":1755674322000},"page":"1684-1687","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2612-1112","authenticated-orcid":false,"given":"Dylan Haixiang","family":"Zhao","sequence":"first","affiliation":[{"name":"Medical Science Division, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Hadley","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pisa","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Saunders","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-5197","authenticated-orcid":false,"given":"Gabriele","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis","volume":"3","author":"Gross CC","year":"2016","unstructured":"Gross CC, Ahmetspahic D, Ruck T, et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e289.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614563522"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0267-5"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102614"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101450"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51130"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000228"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520904277"},{"key":"e_1_3_2_11_2","first-page":"0279","article-title":"Alemtuzumab-induced cytokine release syndrome: An under-appreciated risk in treatment of delayed renal allograft function","volume":"13","author":"Roberts DJ","year":"2020","unstructured":"Roberts DJ, Olyaei A, Rehman S, et al. Alemtuzumab-induced cytokine release syndrome: An under-appreciated risk in treatment of delayed renal allograft function. Trends Transp 2020; 13: 0279.","journal-title":"Trends Transp"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585251365791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585251365791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585251365791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:19:15Z","timestamp":1777695555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585251365791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/13524585251365791"],"URL":"https:\/\/doi.org\/10.1177\/13524585251365791","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}